title: Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
authors.forename: D
authors.initials: D
authors.lastname: González-Bárcena
authors.forename: P
authors.initials: P
authors.lastname: Pérez-Sánchez
authors.forename: A R
authors.initials: AR
authors.lastname: Hernández-Meza
authors.forename: N
authors.initials: N
authors.lastname: Rangel-García
authors.forename: A
authors.initials: A
authors.lastname: Graef-Sánchez
authors.forename: A M
authors.initials: AM
authors.lastname: Comaru-Schally
authors.forename: A V
authors.initials: AV
authors.lastname: Schally
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000502:physiology*; D005951:Glucose Tolerance Test; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017329:Triptorelin Pamoate
chemical_list: D000970:Antineoplastic Agents; D001786:Blood Glucose; D007328:Insulin; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone